SUMMARY The haemodynamic effects of nifedipine were studied in 14 patients (aged 8-14 years, seven male and seven female) with ventricular septal defect with and without pulmonary hypertension. All underwent left and right heart catheterisation. In each patient the pressures and heart rate were measured and blood samples were taken for oximetry before and after sublingual administration of 10 mg nifedipine.
SUMMARY The haemodynamic effects of nifedipine were studied in 14 patients (aged 8-14 years, seven male and seven female) with ventricular septal defect with and without pulmonary hypertension. All underwent left and right heart catheterisation. In each patient the pressures and heart rate were measured and blood samples were taken for oximetry before and after sublingual administration of 10 mg nifedipine.
In eight patients with ventricular septal defect without pulmonary hypertension (mean pulmonary artery pressure < 20 mm Hg) nifedipine significantly reduced the mean aortic pressure and systemic vascular resistance, and significantly increased heart rate. The other haemodynamic indices did not change significantly.
In six patients with ventricular septal defect complicated by pulmonary hypertension (mean pulmonary artery pressure > 20 mm Hg) nifedipine significantly increased systemic output, stroke volume, and heart rate, and significantly reduced systemic vascular resistance and the pulmonary to systemic flow ratio. The other haemodynamic indices did not change significantly.
Nifedipine had a beneficial effect in patients with ventricular septal defect complicated by pulmonary hypertension. It reduced the left to right shunt and increased the stroke volume. This effect was not seen in patients with ventricular septal defect uncomplicated by pulmonary hypertension.
Vasodilators are important and original agents for the treatment of congestive heart failure from various causes.'`Their beneficial effects are more pronounced in the congestive heart failure secondary to valvar regurgitation4and to mechanical complications of acute myocardial infarction.78 The reduction of peripheral vascular resistance has been followed by a substantial improvement of cardiac pump function, increased cardiac output, and attenuation of the clinical signs of venous Accepted for publication 30 November 1987 defect and congestive heart failure confirmed these data.121 '4 This study was designed to evaluate the acute haemodynamic effects of nifedipine in children with ventricular septal defect with and without pulmonary hypertension.
Patients and methods
We studied 14 
Discussion
This study showed that the acute haemodynamic response to nifedipine in patients with ventricular septal defect complicated by pulmonary hypertension differs from that in patients without this complication.
After nifedipine the systemic flow and stroke volume increased and the pulmonary to systemic flow ratio decreased significantly in patients with ventricular septal defect and raised mean pulmonary Acute haemodynamic effects of nifedipine in patients with ventricular septal defect arterial pressure (group B); whereas these variables did not change significantly in patients with ventricular septal defect and normal mean pulmonary artery pressure (group A). Shunting at the ventricular level, with its resultant chronic volume overload, is the basic haemodynamic anomaly in ventricular septal defect. In patients with ventricular septal defect, the haemodynamic conditions in which left ventricular emptying occurs are very similar to those created by mitral regurgitation. The defect in the ventricular septum and the regurgitant mitral valve constitute a low impedance path for a portion of cardiac output.
Lowering left ventricular afterload by means of vasodilators (hydralazine) was associated with a 50% increase in the forward stroke volume and a 33% decrease in the regurgitant volume in a group of patients with mitral regurgitation.4 These changes were dependent upon the extent to which systemic vascular resistance was reduced, as shown by another study of nitrates. performance'2 as did most of group A patients in our study (these indices were normal in five of our eight patients). In fact, in group A patients nifedipine substantially reduced systemic vascular resistance (which was normal in this group as a whole) and mean arterial pressure, increased heart rate without appreciably altering systemic and pulmonary blood flow, pulmonary to systemic flow ratio, mean pulmonary arterial pressure, or pulmonary vascular resistance. Furthermore, systemic vascular resistance was reduced in this group, but this reduction was probably insufficient to induce a significant change in the pulmonary to systemic flow ratio. On the other hand, this group had normal control values for pulmonary vascular resistance. This mechanism is important, however, in patients with ventricular septal defect and abnormally raised systemic vascular resistance. 4 16 Evidence from experimental and clinical studies showed that in patients with small and restrictive ventricular septal defects and normal pulmonary vascular resistance, the amount of the left to right shunt was related to the size of the defect and to the level of systemic vascular resistance; the shunt was augmented by raising the systemic vascular resistance with pressor amines" and lowered by decreasing the raised systemic vascular resistance with vasodilators.' 12 This effect was seen in patient 9, who had a ventricular septal defect of moderate size with raised systemic vascular resistance and normal pulmonary vascular resistance. Nifedipine induced a consistent increase in systemic blood flow and a reduction in the pulmonary to systemic flow ratio, owing to a fall in systemic vascular resistance. By contrast, in patients with a large and non-restrictive ventricular septal defect, the amount of the interventricular shunt was primarily dependent on the pulmonary to systemic resistance ratio'62'; the effects of vasodilators in these patients are therefore determined by the responsiveness of the pulmonary and systemic circulation to these agents. A greater pulmonary to systemic vascular resistance ratio will be associated with a smaller left to right shunt, assuming all other factors remain constant." Vasodilator drugs dilate the systemic and pulmonary vascular bed in patients with congestive heart failure of various aetiologies.'3 Their effect in the pulmonary circulation is not, however, constant. Nifedipine and other vasodilators do not always succeed in lowering pulmonary vascular resistance22; indeed in other studies an increase has been seen.232' This was present in patients 3 and 5 in group B. In patients with large ventricular septal defects, raised pulmonary vascular resistance (owing to functional changes), and normal or slightly increased systemic vascular resistance, vasodilator drugs may affect the pulmonary vascular bed more than the systemic one, thereby increasing the left to right shunt. Similar evidence was derived from studies with nitroprusside718 and hydralazine.'6 The same effect was seen in our patient 7 in whom nifedipine reduced systemic vascular resistance but also reduced pulmonary vascular resistance by 50%, thus increasing the left to right shunt. Preload reduction is important in the increase of pulmonary to systemic flow ratio caused by nitroprusside.'7 Patients with ventricular septal defect, abnormally raised systemic vascular resistance, and reduced systemic blood flow will respond differently to vasodilators, particularly if the pulmonary vascular bed does not react to these agents because of fixed obstructive structural changes. It is the magnitude of reduction of the systemic vascular resistance that determines the decrease in pulmonary to systemic flow ratio and the increase of systemic blood flow in response to vasodilators in this group of patients. Nifedipine considerably reduced systemic vascular resistance, increased systemic blood flow and stroke volume, and reduced the pulmonary to systemic flow ratio in patients with pulmonary hypertension (group B). In this group of patients pulmonary blood flow did not change and, unlike patients without pulmonary hypertension (group A), neither did mean aortic pressure. The increases in systemic blood flow and venous return seem to have prevented the decrease of pulmonary blood flow and mean aortic pressure even in the presence of a reduced left to right shunt and reduced systemic vascular resistance.
The increase in systemic blood flow and venous return seem to have prevented both the diminished left to right shunt from reducing pulmonary blood flow and reduced systemic vascular resistance from lowering mean aortic pressure. The appreciable reduction in systemic vascular resistance was responsible for the significant increase of systemic blood flow and decrease ofpulmonary to systemic flow ratio in our patients because in both groups neither pulmonary vascular resistance nor the left and right ventricular preload showed any significant change in response to nifedipine.
Our study shows that the magnitude of reduction of the systemic vascular resistance by nifedipine in our patients was a function of the pretreatment value because (a) the decrease in systemic vascular resistance was significantly greater in group B (in which systemic vascular resistance was higher) than in group A, and (b) the size of the change in systemic vascular resistance after nifedipine correlated well with its control value. A similar correlation was shown in other studies of vasodilators in patients with congenital or acquired heart disease. In a group of patients with valvar regurgitation the reduction in systemic vascular resistance by nitrates was more pronounced in those with higher control values.5 In another study in patients with large ventricular septal defect and pulmonary hypertension hydralazine caused a larger decrease in systemic vascular resistance (29%) in patients with systemic vascular resistance of > 20 units.m2 than in patients with systemic vascular resistance < 20 units.m2 (only 6%). " We conclude that in patients with ventricular septal defect and pulmonary hypertension, nifedipine significantly reduced Qp/Qs and substantially increased systemic blood flow; this had a beneficial effect on the fundamental haemodynamic disturbance in patients with a left to right shunt. Nifedipine exerts its haemodynamic effect by lowering systemic vascular resistance.
